|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 101 | 2019 | Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial | Cambron, Melissa; Mostert, Jop; D'Hooghe, Marie; Nagels, Guy; Willkens, Barbara; Debruyne, Jan; Algoed, Luc; Verhagen, Winn; Hupperts, Raymond; Heersema, Dorothea; De Keyser, Jacques; De Groot, Liesbeth; Foselle, Erwin; Guillaume, Daniel; Merckx, Henri; Vanopdenbosch, Ludo; Vokaer, Mathieu; DE KLIPPEL, Nina; Nuytten, Dirk; Van Remoortel, Ann; Symons, Anoek; D'haeseleer, Miguel; Bissay, Veronique; Van Merhaegen-Wieleman, Annick; Van Lint, Michel; Michiels, Veronique; Haentjens, Patrick; VAN WIJMEERSCH, Bart; Tillemans, Bart; Van Hecke, Wim; Hengstman, Gerald | Journal Contribution | A1 |
| 102 | 2019 | Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study) | Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 103 | 2019 | Use of other disease-modifying therapies after or between alemtuzumab treatments: pooled results from the CAMMS223, and CARE-MS I and II studies over 8 years | Vermersch, P.; Baker, M.; Bass, A. D.; Berkovich, R.; Comi, G.; Eichau, S.; Graves, D.; Hunter, S. F.; Ionete, C.; Limmroth, V.; Meuth, S. G.; Naismith, R. T.; Sharrack, B.; Subei, A.; Daizadeh, N.; Choudhry, Z.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 104 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 105 | 2019 | Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS | Kalincik, T.; Malpas, C. B.; ROOSEN, Inge; Patti, F.; Butzkueven, H.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Onofrj, M.; Lugaresi, A.; Hupperts, R.; Lechner-Scott, J.; Sola, P.; Ferraro, D.; Grammond, P.; Csepany, T.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; VAN WIJMEERSCH, Bart; Granella, F.; Sa, M. J.; Bergamaschi, R.; Slee, M.; Boz, C.; Ozakbas, S.; Terzi, M.; Prevost, J.; Solaro, C.; Macdonell, R.; Cartechini, E.; Coles, A.; Havrdova, E. K.; Horakova, D. | Journal Contribution | M |
| 106 | 2019 | Effectiveness and safety of Tetrahydrocannabinol - Cannabidiol Oromucosal spray in Belgian patients with multiple sclerosis spasticity: a retrospective data collection | POPESCU, Veronica; Vos, C.; van Dael, V.; Raeymaekers, G.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 107 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 68 | 2019 | A pilot study of the effects of running training on visuospatial memory in MS: A stronger functional embedding of the hippocampus in the default-mode network? | Huiskamp, Marijn; MOUMDJIAN, Lousin; VAN ASCH, Paul; POPESCU, Veronica; Schoonheim, Menno Michiel; Steenwijk, Martijn D.; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Geurts, Jeroen J. G.; FEYS, Peter; Hulst, Hanneke E. | Journal Contribution | A1 |
| 69 | 2019 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | M |
| 70 | 2019 | Predicting long-term sustained disability progression in multiple sclerosis | SHARMIN, Sohely; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Trojano, M.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Terzi, M.; Hupperts, R.; Alroughani, R.; Boz, C.; Shaygannejad, V.; Van Pesch, V.; Cartechini, E.; Kappos, L.; Lechner-Scott, J.; Bergamaschi, R.; Turkoglu, R.; Solaro, C.; Ramo-Tello, C.; Iuliano, G.; Granella, F.; VAN WIJMEERSCH, Bart; Spitaleri, D.; Bolanos, R. F.; Slee, M.; McCombe, P.; Prevost, J.; Ampapa, R.; Ozakbas, S.; Sanchez-Menoyo, J. L.; Soysal, A.; Vucic, S.; Petersen, T.; Verheul, F.; Butler, E.; Hodgkinson, S.; Sidhom, Y.; Gouider, R.; Butzkueven, H.; Kalincik, T. | Journal Contribution | M |
| 71 | 2019 | Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis | SHARMIN, Sohely; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Ozakbas, S.; Butzkueven, H.; Patti, F.; Onofrj, M.; Lugaresi, A.; Terzi, M.; Grammond, P.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; Boz, C.; Trojano, M.; McCombe, P.; Slee, M.; Lechner-Scott, J.; Turkoglu, R.; Sola, P.; Ferraro, D.; Granella, F.; Shaygannejad, V.; Prevost, J.; Skibina, O.; Solaro, C.; Karabudak, R.; VAN WIJMEERSCH, Bart; Csepany, T.; Spitaleri, D.; Vucic, S.; Leray, E.; Sorensen, P. S.; Sellebjerg, F.; Magyari, M.; Vukusic, S.; Kalincik, T. | Journal Contribution | M |
| 72 | 2019 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings | Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; de Seze, Jerome; Dela Cruz, Dionisio; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 73 | 2019 | Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD-CD27- Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients | FRAUSSEN, Judith; Marquez, Susanna; Takata, Kazushiro; BECKERS, Lien; MONTES DIAZ, Gwendoline; Zografou, Chrysoula; VAN WIJMEERSCH, Bart; Villar, Luisa M.; O'Connor, Kevin C.; Kleinstein, Steven H.; SOMERS, Veerle | Journal Contribution | A1 |
| 74 | 2019 | IgD(-)CD27(-) double negative B cells of multiple sclerosis patients have a pro-inflammatory migratory phenotype and function | BECKERS, Lien; Diaz, G. Montes; Villar, L. M.; VAN WIJMEERSCH, Bart; SOMERS, Veerle; FRAUSSEN, Judith | Journal Contribution | M |
| 75 | 2018 | Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) | Vermersch, Patrick; Coles, Alasdair J.; Boyko, Alexey N.; De Seze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; McCombe, Pamela; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 76 | 2018 | Durable clinical efficacy of alemtuzumab in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study) | McCombe, Pamela; Boyko, Alexey N.; DeSeze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Vermersch, Patrick; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 77 | 2018 | Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) | Steingo, Brian; Oreja-Guevara, Celia; Alroughani, Raed; Brassat, David; Boyko, Alexey N.; McCombe, Pamela; VAN WIJMEERSCH, Bart; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; Vermersch, Patrick | Journal Contribution | M |
| 78 | 2018 | Treatment Experiences of Patients with MS: Results From the Global vs MS (TM) Survey | Bass, Ann; VAN WIJMEERSCH, Bart; Boster, Aaron; Mayer, Lori; Mandel, Matt; Sharrock, Kersten; Mitchell, Colin P.; Singer, Barry | Journal Contribution | M |
| 79 | 2018 | Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) | VAN WIJMEERSCH, Bart; Boyko, Alexey N.; Broadley, Simon; Brassat, David; Dive, Dominique; Hupperts, Raymond M. M.; Lycke, Jan; Montalban, Xavier; Sharrack, Basil; Wray, Sibyl; Margolin, David H.; Chung, Luke; Daizadeh, Nadia; Chirieac, Madalina; Wiendl, Heinz | Journal Contribution | M |
| 80 | 2018 | Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis. | MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, Paul | Journal Contribution | A1 |
Loading...
5
0
5
0
false